Evaluation of factors affecting smoking cessation in people treated with Varenicline
Article Sidebar
Main Article Content
Abstract
Objective: Aim of the study is to evaluate factors affecting treatment success among individuals receiving varenicline therapy for smoking cessation.
Material and Methods: This research was carried out at Istanbul Medeniyet University Göztepe Training and Research Hospital between January 2018 and January 2019. A total of 209 patients in the smoking cessation outpatient clinic who were treated with varenicline Varenicline were constituted into the study group. The Fagerstrom Nicotine Dependence Level Test (FTND) was used to determine individuals' nicotine addiction levels, and the Hospital Anxiety and Depression Scale (HADS) was used to evaluate anxiety and depression levels.
Results: There were 90 (43.1%) women and 119 (56.9%) men in the study group and mean age was 41.34 ± 10.93 (21-64) years. Overall, 63.2% (n=132) of varenicline recipients quit smoking. The frequency of quitting smoking due to physician advice was higher in those who quit than those who did not (p=0.011). Multiple logistic regression revealed that the independent factors associated with the lower likelihood of smoking cessation were higher number of cigarettes per day (p=0.008), higher HADS-Total score (p<0.001), post-treatment nervousness (p=0.046), and post-treatment depressive mood (p=0.007), whereas being able to remain smoke-free for longer periods in previous quitting attempts was associated with higher likelihood of success (p=0.005).
Conclusion: The success of smoking cessation with varenicline therapy is lower in the presence of the following factors: having high risk for anxiety and depression, smoking a greater number of cigarettes per day, shorter periods of remaining smoke-free in previous quitting attempts, and experiencing nervousness during withdrawal. Receiving physician advice to quit also appears to increase the chance of quitting smoking.
Keywords: Smoking; Smoking Cessation; Smoking Cessation Agents; Varenicline; Anxiety; Depression
Downloads
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Accepted 2022-09-28
Published 2022-09-28
References
WHO, Assessment of the Economic Costs of Smoking Available from: http://apps.who.int/iris/bitstream/handle/10665/44596/9789241501576_eng.pdf;jsessionid=AE2D3D8F6FFD7926B13820E6DA2E4F96?sequence=1, access date: 22.05.2022.
Jha, P., et al., 21st-century hazards of smoking and benefits of cessation in the United States. New England Journal of Medicine. 2013;368(4):341-50. DOI: https://doi.org/10.1056/NEJMsa1211128
Ferri, C., Strategies for reducing the risk of cardiovascular disease in patients with chronic obstructive pulmonary disease. High Blood Pressure & Cardiovascular Prevention. 2015;22(2):103-11. DOI: https://doi.org/10.1007/s40292-015-0078-3
Giulietti, F., et al., Pharmacological Approach to Smoking Cessation: An Updated Review for Daily Clinical Practice. High Blood Press Cardiovasc Prev. 2020;27(5):349-62. DOI: https://doi.org/10.1007/s40292-020-00396-9
Cahill, K., et al., Nicotine receptor partial agonists for smoking cessation. Cochrane database of systematic reviews. 2016;9(5):CD006103. DOI: https://doi.org/10.1002/14651858.CD006103.pub7
Baker, C.L. and G. Pietri, A cost-effectiveness analysis of varenicline for smoking cessation using data from the EAGLES trial. Clinico Economics and Outcomes Research. 2018;10:67-74. DOI: https://doi.org/10.2147/CEOR.S153897
Anthenelli, R.M., et al., Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial. The Lancet. 2016; 387(10037):2507-20. DOI: https://doi.org/10.1016/S0140-6736(16)30272-0
Kalkhoran, S., N.L. Benowitz, and N.A. Rigotti, Prevention and Treatment of Tobacco Use: JACC Health Promotion Series. Journal of the American College of Cardiology. 2018;72(9):1030-45. DOI: https://doi.org/10.1016/j.jacc.2018.06.036
Gilbody, S., et al., Smoking cessation for people with severe mental illness (SCIMITAR+): a pragmatic randomised controlled trial. The Lancet Psychiatry. 2019;6(5):379-90. DOI: https://doi.org/10.1016/S2215-0366(19)30047-1
Uysal, M.A., et al., Fagerstrom test for nicotine dependence: reliability in a Turkish sample and factor analysis. Tuberk Toraks J. 2004;52(2):115-21.
Heatherton, T.F., et al., The Fagerström test for nicotine dependence: a revision of the Fagerstrom Tolerance Questionnaire. British journal of addiction. 1991;86(9):1119-27. DOI: https://doi.org/10.1111/j.1360-0443.1991.tb01879.x
Zigmond, A.S. and R.P. Snaith, The hospital anxiety and depression scale. Acta Psychiatrica Scandinavica. 1983;67(6):361-70. DOI: https://doi.org/10.1111/j.1600-0447.1983.tb09716.x
Aydemir, O., Hastane anksiyete ve depresyon olcegi Turkce formunun gecerlilik ve guvenilirligi. Turk Psikiyatri Derg. 1997;8:187-280.
Perez-Paramo, Y.X. and P. Lazarus, Pharmacogenetics factors influencing smoking cessation success; the importance of nicotine metabolism. Expert Opinion on Drug Metabolism & Toxicology. 2021;17(3):333-49. DOI: https://doi.org/10.1080/17425255.2021.1863948
Liberman, J.N., et al., Adherence to Varenicline and Associated Smoking Cessation in a Community-Based Patient Setting. Journal of Managed Care Pharmacy. 2013;19(2):125-31. DOI: https://doi.org/10.18553/jmcp.2013.19.2.125
Ebbert, J.O., et al., Effect of Varenicline on Smoking Cessation Through Smoking Reduction: A Randomized Clinical Trial. JAMA. 2015;313(7):687-94. DOI: https://doi.org/10.1001/jama.2015.280
Buczkowski, K., et al., Motivations toward smoking cessation, reasons for relapse, and modes of quitting: results from a qualitative study among former and current smokers. Patient Preference Adherence. 2014;8:1353-63. DOI: https://doi.org/10.2147/PPA.S67767
Dickens, G.L., J. Staniford, and C.G. Long, Smoking behaviour, motives, motivation to quit and self‐efficacy among patients in a secure mental health service: comparison with staff controls. Journal of Psychiatric and Mental Health Nursing. 2014;21(6):483-90. DOI: https://doi.org/10.1111/jpm.12088
Villanti, A.C., et al., Reasons to quit and barriers to quitting smoking in US young adults. Family Practice. 2016;33(2):133-9. DOI: https://doi.org/10.1093/fampra/cmv103
Yaşar, Z., et al., One-year follow-up results of smoking cessation outpatient clinic: factors affecting the cessation of smoking. Eurasian J Pulmonol. 2014;16(2):99-104. DOI: https://doi.org/10.5152/ejp.2014.48295
Guo, K., et al., The effect of Varenicline and Bupropion on smoking cessation: A network meta-analysis of 20 randomized controlled trials. Addictive Behaviors. 2022;131:107329. DOI: https://doi.org/10.1016/j.addbeh.2022.107329
Koegelenberg, C.F., et al., Efficacy of varenicline combined with nicotine replacement therapy vs varenicline alone for smoking cessation: a randomized clinical trial. JAMA. 2014;312(2):155-161. DOI: https://doi.org/10.1001/jama.2014.7195
Baker, T.B., et al., Effects of Combined Varenicline With Nicotine Patch and of Extended Treatment Duration on Smoking Cessation: A Randomized Clinical Trial. JAMA. 2021;326(15):1485-93. DOI: https://doi.org/10.1001/jama.2021.15333
Lindberg, A., et al., Low nicotine dependence and high self-efficacy can predict smoking cessation independent of the presence of chronic obstructive pulmonary disease: a three year follow up of a population-based study. Tobacco Induced Diseases. 2015;13(1):27. DOI: https://doi.org/10.1186/s12971-015-0055-6
Eum, Y.H., et al., Factors related to the success of smoking cessation: A retrospective cohort study in Korea. Tobacco Induced Diseases. 2022;20:15. DOI: https://doi.org/10.18332/tid/144272
Minichino, A., et al., Smoking behaviour and mental health disorders--mutual influences and implications for therapy. International Journal of Environmental Research and Public Health. 2013;10(10):4790-811. DOI: https://doi.org/10.3390/ijerph10104790
Klemperer, E.M., et al., Predictors of Smoking Cessation Attempts and Success Following Motivation-Phase Interventions Among People Initially Unwilling to Quit Smoking. Nicotine & Tobacco Research. 2020;22(9):1446-52. DOI: https://doi.org/10.1093/ntr/ntaa051